Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
AstraZeneca’s experimental pill camizestrant significantly reduced the risk of disease progression or death in hormone receptor-positive, HER2-negative breast cancer, according to new data presented at the American Society of Clinical Oncology (ASCO) meeting. In the trial, patients switched to camizestrant after early signs of resistance detected through a blood-based liquid biopsy showed a 56% improvement in progression-free survival compared to standard therapy.
This marks the first time liquid biopsy has been used to guide treatment decisions before visible tumor growth. Dr. Eleonora Teplinsky of Valley-Mount Sinai said the early switch approach allows oncologists to “stay ahead of the curve,” potentially changing how breast cancer is treated.
The phase 3 study enrolled 3,256 women with advanced HR-positive, HER2-negative breast cancer. After at least six months of aromatase inhibitors and CDK4/6 inhibitors—like Kisqali (Novartis), Ibrance (Pfizer), or Verzenio (Eli Lilly)—315 patients with ESR1 mutations were identified and randomized. Patients receiving camizestrant plus a CDK4/6 inhibitor saw a median of 16 months without disease progression, versus 9.2 months on standard therapy with placebo.
No new safety issues were reported, and dropout rates remained low. Camizestrant is a selective estrogen receptor degrader (SERD), designed to block estrogen signaling in cancer cells—an alternative when standard hormone therapies lose effectiveness.
In a separate trial, AstraZeneca’s immunotherapy Imfinzi (durvalumab), combined with FLOT chemotherapy, reduced the risk of disease recurrence or death by 29% in early-stage gastric and esophageal cancer patients. The findings support earlier intervention with immunotherapy and are expected to influence global treatment practices.
AstraZeneca CEO Pascal Soriot emphasized the importance of proactive monitoring, calling it the future of cancer care. Both studies were simultaneously published in the New England Journal of Medicine.
